Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
Conor Chandlera Evidera Inc, Waltham, MA, United States of America
https://orcid.org/0000-0002-1365-9002View further author information
https://orcid.org/0000-0002-1365-9002View further author information, Heather Burnettb Evidera Inc, St-Laurent, Canadahttps://orcid.org/0000-0003-1269-4276View further author information
https://orcid.org/0000-0003-1269-4276View further author information, Kassandra Schaiblea Evidera Inc, Waltham, MA, United States of Americahttps://orcid.org/0000-0002-7822-3090View further author information
https://orcid.org/0000-0002-7822-3090View further author information, Vishnu Senthila Evidera Inc, Waltham, MA, United States of Americahttps://orcid.org/0000-0001-6898-8826View further author information
https://orcid.org/0000-0001-6898-8826View further author information, Masafumi Katoc Market Access, Public Affairs & Patient Experience, Takeda Pharmaceutical Company Ltd, Tokyo, Japanhttps://orcid.org/0000-0002-3813-1220View further author information
https://orcid.org/0000-0002-3813-1220View further author information, Yuji Miurad Department of Medical Oncology, Toranomon Hospital, Tokyo, Japanhttps://orcid.org/0000-0002-7091-628XView further author information
https://orcid.org/0000-0002-7091-628XView further author information, Takahiro Osawae Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japanhttps://orcid.org/0000-0003-4444-7958View further author information
https://orcid.org/0000-0003-4444-7958View further author information, Hiroji Uemuraf Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-7943-1564View further author information
https://orcid.org/0000-0001-7943-1564View further author information & Hiroyo Kuwabarac Market Access, Public Affairs & Patient Experience, Takeda Pharmaceutical Company Ltd, Tokyo, Japanhttps://orcid.org/0000-0001-6086-6453View further author information
https://orcid.org/0000-0001-6086-6453View further author information show all